Synergy Pharmaceuticals (SGYP) +18.4% after the company says that its plecanatide oral treatment...

|About: Synergy Pharmaceuticals, ... (SGYP)|By:, SA News Editor

Synergy Pharmaceuticals (SGYP) +18.4% after the company says that its plecanatide oral treatment for chronic constipation due to an unknown cause met the primary and secondary goals of a Phase IIb/III study. Chronic constipation is the most common digestive complaint in the world, with about 15%, or 45M people, suffering in the U.S. (PR)